scispace - formally typeset
V

Veronica Escalante

Researcher at University of California, San Francisco

Publications -  6
Citations -  95

Veronica Escalante is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Metabolic network & Metabolomics. The author has an hindex of 2, co-authored 4 publications receiving 27 citations. Previous affiliations of Veronica Escalante include University of California, Berkeley.

Papers
More filters
Journal ArticleDOI

Bacterial alginate regulators and phage homologs repress CRISPR-Cas immunity.

TL;DR: The identification of the KinB–AlgB two-component system, known to modulate alginate biosynthesis, together with downstream proteins that repress the Type I-F CRISPR–Cas system in Pseudomonas aeruginosa, elucidates how bacteria control the expression of nucleolytic host defence systems to minimize the potential risks of self-targeting.
Journal ArticleDOI

A thermogenic fat-epithelium cell axis regulates intestinal disease tolerance

TL;DR: Evidence is provided that a thermogenic fat–epithelial cell axis regulates intestinal disease tolerance during experimental colitis, and it is found that the program of disease tolerance is preferentially expressed in thermoneutral mice, which protects them from injury-induced colitis and inflammation-induced colon cancer.
Posted ContentDOI

Systems biology illuminates alternative metabolic niches in the human gut microbiome

TL;DR: Stable isotope-resolved metabolomics revealed that E. lenta uses acetate as a key carbon source while catabolizing arginine to generate ATP, traits which could be recapitulated in silico by the updated metabolic model.
Posted ContentDOI

CRISPR-Cas immunity repressed by a biofilm-activating pathway in Pseudomonas aeruginosa

TL;DR: A forward genetic screen identifies a two-component system (KinB/AlgB), previously characterized in regulating Pseudomonas aeruginosa virulence and biofilm establishment, as a regulator of the biogenesis and activity of the Type I-F CRISPR-Cas system.